Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1964 1
1982 2
1985 1
1986 2
1987 5
1988 3
1991 1
1994 1
1995 1
1997 1
1998 1
2000 1
2002 2
2004 6
2005 15
2006 13
2007 6
2008 8
2009 9
2010 23
2011 21
2012 15
2013 19
2014 16
2015 15
2016 12
2017 7
2018 12
2019 15
2020 14
2021 16
2022 17
2023 22
2024 35
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Prevalence of uveitis in syphilis patients in Taiwan.
Chen CY, Kuo HT, Hsu AY, Lin CJ, Hsia NY, Tien PT, Lai CT, Chen HS, Tsai YY. Chen CY, et al. Among authors: kuo ht. Emerg Microbes Infect. 2024 Dec;13(1):2290836. doi: 10.1080/22221751.2023.2290836. Epub 2024 Jan 22. Emerg Microbes Infect. 2024. PMID: 38047718 Free PMC article.
Cataract Development Among Pediatric Patients With Uveitis.
Hsu AY, Kuo HT, Lin CJ, Hsia NY, Kuo SC, Wei CC, Lai CT, Chen HS, Wang YH, Wei JC, Tsai YY. Hsu AY, et al. Among authors: kuo ht. JAMA Netw Open. 2024 Jul 1;7(7):e2419366. doi: 10.1001/jamanetworkopen.2024.19366. JAMA Netw Open. 2024. PMID: 38949811 Free PMC article.
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. J Am Soc Nephrol. 2024 Oct 25. doi: 10.1681/ASN.0000000534. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39455063 No abstract available.
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Lu MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML; TACR Study Group. Lu MY, et al. Among authors: kuo ht. Clin Mol Hepatol. 2024 Jan;30(1):64-79. doi: 10.3350/cmh.2023.0287. Epub 2023 Nov 21. Clin Mol Hepatol. 2024. PMID: 38195113 Free PMC article.
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.
Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Chung WL, Bair MJ, Yu ML; T-COACH Study Group. Tsai PC, et al. Among authors: kuo ht. Clin Mol Hepatol. 2024 Jul;30(3):468-486. doi: 10.3350/cmh.2024.0038. Epub 2024 Apr 19. Clin Mol Hepatol. 2024. PMID: 38637957 Free PMC article.
Hydranencephaly in neonates.
Tsai JD, Kuo HT, Chou IC. Tsai JD, et al. Among authors: kuo ht. Pediatr Neonatol. 2008 Aug;49(4):154-7. doi: 10.1016/S1875-9572(08)60032-7. Pediatr Neonatol. 2008. PMID: 19054923 Free article.
304 results